Brand and Other Names:Tikosyn
- Classes: Antidysrhythmics, III
Dosing & Uses
Dosage Forms & Strengths
Conversion of Atrial Fibrillation/Flutter to Normal Sinus Rhythm
QTc must be <440 msec (or <500 msec with ventricular conduction abnormalities) before initiating first dose; contraindicated if >440 msec (or >500 msec with ventricular conduction abnormalities)
- CrCl >60 mL/min: 500 mcg PO q12hr
- CrCl 40-60 mL/min: 250 mcg PO q12hr
- CrCl 20-40 mL/min: 125 mcg PO q12hr
- CrCl <20 mL/min: Contraindicated
Sinus Rhythm Maintenance After Conversion
- Post initial dose adjustment based on QTc (2-3 hours after initial dose)
- If QTc increases <15% of baseline, continue current dose
- If QTc increases >15% or >500 msec (550 msec with ventricular conduction abnormalities) decrease dose as follows:
- If initial dose 500 mcg q12hr, decrease to 250 mcg q12hr
- If initial dose 250 mcg q12hr, decrease to 125 mcg q12hr
- If initial dose 125 mcg q12hr, decrease to 125 mcg qDay
Must be hospitalized to initiate
Measure QTc 2-3 hours after first 5 doses during inpatient stay
Discontinue dofetilide if at any time after second dose, QTC >500 msec (550 msec with ventricular conduction abnormalities)
Serious - Use Alternative
Significant - Monitor Closely
Chest pain (10%)
Respiratory tract infection (7%)
Flu-like syndrome (4%)
Back pain (3%)
Ventricular tachycardia (3-4%)
Torsade de pointes (3% in HF patients and 0.9% in patients with recent MI)
Frequency Not Defined
AV block, QTc interval prolongation, torsades de pointes, ventricular arrhythmias
Black Box Warnings
Hospitalize minimum of 3 days during initiation or reinitiation to minimize risk of induced arrhythmia
Facility must provide CrCl calculations, continuous ECG monitoring, and resuscitation for at least 3 days when initiating or restarting therapy
Experienced personnel who manage serious arrhythmias & setting required
- Baseline & continuous ECG during therapy
- Do not initiate if baseline QTc >440 msec (500 msec in patients w/ ventricular conduction problems)
- Do not initiate if heart rate <60 bpm
- Baseline CrCl determines initial dosage; dosage adjustments determined by QTc changes
- Reevaluate renal function and QTc q3mth or more often if medically required
Congenital or acquired long QT syndromes; do not use with baseline QTc >440 msec (500 msec with ventricular conduction abnormalities)
Concomitant use of cation transport system inhibitors (eg, verapamil, cimetidine, trimethoprim, ketoconazole, prochlorperazine, dolutegravir and megestrol); each of these drugs cause a substantial increase in dofetilide plasma concentrations
Severe renal impairment: CrCl <20 mL/min
Atrioventricular block, bradycardia, electrolyte imbalance, patients taking potassium-depleting diuretics, moderate QT interval prolongation prior to treatment, proarrhythmic events, liver disease, renal impairment
Coadministration of drugs that prolong QT interval and other antiarrhythmic agents: phenothiazines, cisapride, bepridil, TCAs, oral macrolides, class I or class III antiarrhythmics & amiodarone
Grapefruit juice may increase levels; avoid concurrent use
Magnesium and potassium serum levels should be maintained within normal range to avoid QTc prolongation
Pregnancy & Lactation
Pregnancy Category: C
Lactation: excretion in milk unknown/not recommended
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Blocks channels carrying delayed rectifier potassium currents, IKr
Markedly prolongs action potential as a result of delayed repolarization
Peak Plasma Time: 2-3 hr
Onset: 2 hr
Duration: 4 hr
Protein Bound: 60-70%
Vd: 3-4 L/kg
50% of absorbed dose metabolized in liver by CYP3A4 to inactive metabolites
Metabolites: No quantifiable metabolites found in plasma, 5 metabolites identified in urine
Half-Life: 10 hr
Excretion: 80% urine; <10% feces
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs